Neurolixis Inc. is an early-stage biopharmaceutical company developing novel treatments for disorders of the central nervous system. Neurolixis is advancing its drug discovery and development programs and has a promising drug development pipeline:


Therapeutic focus

Neurolixis exploits novel neuronal mechanisms to improve therapy of serious central nervous system disorders, including Parkinson's disease, Rett syndrome, depression and pain. More...


Neurolixis is developing in-licensed early clinical assets with innovative profiles (NLX-112 and NLX-101) and also identifying and developing proprietary Novel Chemical Entities (NCEs). More...


Neurolixis places high value on pharmacological target validation. Studies describing its clinical assets have been published in peer-reviewed journals. More...


Follow Neurolixis on: